Alpha-lipoic acid modifies circulating angiogenic factors in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 107, Issue 2, 2015, Pages 273-279

  Dworacka, Marzena ^a   Iskakova, Saule ^b   Krzyzagórska, Ewa ^c   Wesołowska, Anna ^a   Kurmambayev, Yergen ^b   Dworacki, Grzegorz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WEST KAZAKHSTAN MARAT OSPANOV STATE MEDICAL UNIVERSITY   (Kazakhstan)

^c Poznan Specialist Center of Medical Care   (Poland)

Author keywords

Alpha lipoic acid; BFGF; IL 10; MCP 1; Type 2 diabetes; VEGF

Indexed keywords

ANGIOGENIN; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 10; INTERLEUKIN 12; MONOCYTE CHEMOTACTIC PROTEIN 1; THIOCTIC ACID; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SENSORIMOTOR NEUROPATHY;

EID: 84964241026     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.11.005     Document Type: Article

References (45)

1. Costa P.Z., Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci 2013, 92(22):1037-1045.
2. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009, 20(4):158-163.
3. Yun Y.R., Won J.E., Jeon E., Lee S., Kang W., Jo H., et al. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng 2010, 1. 10.4061/2010/218142.
4. Niu J., Kolattukudy P. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci 2009, 117:95-109.
5. Saxena S.K., Rybak S.M., Davey R.T., Youle R.J., Ackerman E.J. Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J Biol Chem 1992, 30:21982-21986.
6. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007, 13(16):4677-4685.
7. Silvestre J-S., Mallat Z., Duriez M., Tamarat R., Bureau M.F., Scherman D., et al. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2000, 87:448-452.
8. Smith A.R., Shenvi S.V., Widlansky M., Suh J.H., Hagen T.M. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004, 11:1135-1146.
9. Micili S.C., Goker A., Sayin O., Akokay P., Ergur B.U. The effect of lipoic acid on wound healing in a full thickness uterine model in rats. J Mol Histol 2013, 44(3):339-345.
10. Larghero P., Venè R., Minghelli S., Travaini G., Morini M., Ferrari N., et al. Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression. Carcinogenesis 2007, 28(5):1008-1020.
11. Lee S.G., Lee C.G., Yun I.H., Hur D.Y., Yang J.W., Kim H.W. Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina. Clin Experiment Ophthalmol 2012, 40(1):e47-e57.
12. Nebbioso M., Pranno F., Pescosolido N. Lipoic acid in animal models and clinical use in diabetic retinopathy. Expert Opin Pharmacother 2013, 14(13):1829-1838.
13. Boulton A.J., Kempler P., Ametov A., Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy?. Diabetes Metab Res Rev 2013, 29(5):327-333.
14. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 2011, 7(3):208-220.
15. Vinik A.I., Park T.S., Stansberry K.B., Pittenger G.L. Diabetic neuropathies. Diabetologia 2000, 43:957-973.
16. Xu Q., Pan J., Yu J., Liu X., Liu L., Zuo X., et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract 2013, 101(2):99-105. 10.1016/j.diabres.2013.03.033.
17. Nagamatsu M., Nickander K.K., Schmelzer J.D., Raya A., Wittrock D.A., Tritschler H., et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995, 18:1160-1167.
18. Sola S., Mir M.Q., Cheema F.A., Khan-Merchant N., Menon R.G., Parthasarathy S., et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005, 111:343-348.
19. Heitzer T., Finckh B., Albers S., Krohn K., Kohlschütter A., Meinertz T. Beneficial effects of α-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001, 31:53-61.
20. Malik R.A., Tesfaye S., Newrick P.G., Walker D., Rajbhandari S.M., Siddique I., et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005, 48:578-585.
21. Schratzberger P., Walter D.H., Rittig K., Bahlmann F.H., Pola R., Curry C., et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001, 107:1083-1092.
22. Da Ros R., Assaloni R., Ceriello A. Molecular targets of diabetic vascular complications and potential new drugs. Curr Drug Targets 2005, 6:503-509.
23. Bansilal S., Farkouh M.E., Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 2007, 99(4A):6B-14B.
24. Chen C.-H., Walterscheid J.P. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ Res 2006, 99:787-789.
25. Benjamin L. Glucose, VEGF-A, and diabetic complications. Am J Pathol 2001, 4:1181-1184.
26. Simons M. Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed?. J Am Coll Cardiol 2005, 5:835-837.
27. Lee J.E., Yi C.O., Jeon B.T., Shin H.J., Kim S.K., Jung T.S., et al. α-Lipoic acid attenuates cardiac fibrosis in Otsuka Long-Evans Tokushima Fatty rats. Cardiovasc Diabetol 2012, 11:111.
28. Ying Z., Kherada N., Farrar B., Kampfrath T., Chung Y., Simonetti O., et al. Lipoic acid effects on established atherosclerosis. Life Sci 2010, 86(3-4):95-102.
29. Dworacka M., Winiarska H., Szymańska M., Kuczyński S., Szczawińska K., Wierusz-Wysocka B. 1,5-Anhydro-d-glucitol: a novel marker of glucose excursions. Int J Clin Pract Suppl 2002, 129:40-44.
30. Chusney G.D., Philippa M., Pickup J.C. Comparison of micro-enzymatic and high performance liquid chromatographic methods for the assay of serum 1,5-anhydroglucitol. Clin Chim Acta 1995, 235:91-99.
31. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003, 163(11):1306-1316.
32. Weykamp C., John W.G., Mosca A., Hoshino T., Little R., Jeppsson J.O., et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 2008, 54(2):240-248.
33. Zacchigna S., Lambrechts D., Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008, 9:169-181.
34. Konrad D., Somwar R., Sweeney G., Yaworsky K., Hayashi M., Ramlal T., et al. The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes 2001, 50(6):1464-1471.
35. Estrada D.E., Ewart H.S., Tsakiridis T., Volchuk A., Ramlal T., Tritschler H., et al. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes 1996, 45(12):1798-1804.
36. Zhang W.J., Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NFkappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001, 15:2423-2432.
37. Evans J.L., Goldfine I.D. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000, 2(3):401-413.
38. Blann A.D., Belgore F.M., McCollum C.N., Silverman S., Lip P.L., Lip G.Y. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002, 102:187-194.
39. Motawi T.K., Rizk S.M., Ibrahim I.A., El-Emady Y.F. Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy. Cell Biochem Funct 2013, [Epub ahead of print]. 10.1002/cbf.2987.
40. Deguchi T., Hashiguchi T., Horinouchi S., Uto T., Oku H., Kimura K., et al. Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage. Diabetes Metab 2009, 26(3):247-252.
41. Muthuraman A., Ramesh M., Sood S. Development of animal model for vasculatic neuropathy: induction by ischemic-reperfusion in the rat femoral artery. J Neurosci Methods 2010, 186(2):215-221.
42. White F.A., Feldman P., Miller R.J. Chemokine signaling and the management of neuropathic pain. Mol Interv 2009, 9(4):188-195.
43. Veves A., King G.L. Can VEGF reverse diabetic neuropathy in human subjects?. J Clin Invest 2001, 107(10):1215-1218.
44. Nakae M., Kamiya H., Naruse K., Horio N., Ito Y., Mizubayashi R., et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes 2006, 55(5):1470-1477.
45. Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans 2009, 37:1167-1170.